A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
Status
Terminated
Conditions
Metastatic Breast Cancer
Treatments
Other: No intervention
Details and patient eligibility
About
This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.
Enrollment
15 patients
Sex
All
Ages
18+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- Initially diagnosed with HER2-positive unresectable LA/mBC no more than 6 months prior to enrollment
- Able to comply with the study protocol
Exclusion criteria
None
Trial design
15 participants in 1 patient group
Participants with HER2-positive unresectable LA/mBC
Treatment:
Other: No intervention
Trial contacts and locations
3
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2024 Veeva Systems